NEW YORK (Reuters Health)—Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest. “It’s reassuring for mothers who need to take these medications during pregnancy,” Evelyne Vinet, MD, of McGill University Health Center in…
Improved Family Planning Counseling Needed
In the U.S. today, approximately 45% of pregnancies are unintended or unplanned.1 Although this rate is considerably lower than in the past, women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or inflammatory myopathies tend to have better pregnancy outcomes if their disease is well controlled when they conceive. In addition, women taking certain medications…
Family Planning Counseling & the Rheumatologist
Women with rheumatic diseases have unique reproductive health needs, and family planning counseling is a critical component to their overall healthcare. A new research review examines the barriers to patients with rheumatic disease receiving family planning counseling. Additionally, reviewers provide rheumatologists with practical suggestions to optimize communication with patients, as well as address the effect of medications and the effectiveness of contraception…
EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…
Rheumatic Disease Does Not Preclude Pregnancy
Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…
Rheumatology Case Report: Monoarticular Arthritis in Pregnancy
Limited data exist on the clinical presentation of Muckle–Wells syndrome (MWS) during pregnancy. The purpose of this case report is to highlight the diagnosis of MWS in a pregnant woman. Many rheumatic diseases affect women of childbearing age, and their management during pregnancy can be challenging. Case A 33-year-old, 18-weeks’ pregnant woman was hospitalized for…
New Studies Examine Impact of Poverty, Race, Ethnicity in Patients with SLE
To correctly address a problem, one must have a handle on its nuances—a clear understanding of what is linked and how. And thus far, when it comes to lupus, we haven’t reached the point of understanding those intricacies. Things are heading in the right direction, however, with two new studies that get us much closer…
Paternal Methotrexate Exposure Not Tied to Adverse Pregnancy Outcomes
NEW YORK (Reuters Health)—A father’s exposure to methotrexate 90 days or less before conception “should not be of major concern,” researchers say. Prepregnancy paternal methotrexate exposure appears to confer no increased risk of major or minor congenital malformation, stillbirth or preterm birth in his offspring, their study found. Methotrexate is a first-line therapy for rheumatoid…
Certolizumab Pegol Usage Compatible with Breastfeeding
In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…
Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy
The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- Next Page »